Directorate change
Directorate change
December 4, 2015 - Shire plc (LSE: SHP, NASDAQ: SHPG) announces the following appointments to committees of the Board with effect from December 3, 2015:
|
Director1 |
Board committee |
|
Steven Gillis2 |
Audit, Compliance & Risk Committee |
|
David Ginsburg |
Nomination Committee |
|
Sara Mathew |
Remuneration Committee |
1. Each director will serve as a member of the respective Board committee.
2. Dr. Gillis has served as an interim member of the Audit, Compliance & Risk Committee since December 3, 2014.
Oliver Strawbridge
Senior Assistant Company Secretary
For further information please contact:
|
Investor Relations |
|
|
|
Matthew Osborne |
+1 781 482 9502 | |
|
Sarah Elton-Farr |
+44 1256 894157 |
NOTES TO EDITORS
Shire enables people with life-altering conditions to lead better lives.
Our strategy is to focus on developing and marketing innovative specialty medicines to meet significant unmet patient needs.
We focus on providing treatments in Rare Diseases, Neuroscience, Gastrointestinal and Internal Medicine and we are developing treatments for symptomatic conditions treated by specialist physicians in other targeted therapeutic areas, such as Ophthalmics.